Statin Use and the Risk of Proliferative Vitreoretinopathy in Eyes Undergoing Rhegmatogenous Retinal Detachment Repair.

Authors

Sidra Zafar, Nitika Aggarwal, Sudheshna Vemula, Turner Wibbelsman, Josee Winsor, Nick Boucher, Ajay E Kuriyan, Yoshihiro Yonekawa

Published in

Ophthalmic surgery, lasers & imaging retina. Pages 1-6. Jul 29, 2026. Epub Jul 29, 2026.

Abstract

This study aimed to evaluate the association between statin use and frequency of proliferative vitreoretinopathy (PVR) and return to the operating room in eyes undergoing rhegmatogenous retinal detachment (RRD) repair.
This was a retrospective study of all patients ≥18 years of age who underwent RRD repair between January 2015 and November 2024, identified in the Vestrum Health Retina Database.
A total of 54,876 eyes were included in the final analysis, of which 17,922 (33%) were taking statins. The frequency of PVR development within 90 days following primary RRD repair was significantly lower in the statin group compared to the non-statin group (6.67% vs. 8.17%, P < .001). In a multivariate regression analysis adjusted for age, sex, smoking history, lens status, diabetes, and surgery type, statin use was independently associated with a decreased likelihood of PVR (odds ratio: 0.70, 95% CI: 0.66 to 0.75).
Statin use was associated with a significantly lower risk for PVR formation and return to the operating room following primary RRD repair.

PMID:
42555830
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.